<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: To evaluate the within-trial effect of <z:chebi fb="0" ids="6541">losartan</z:chebi> and conventional <z:chebi fb="0" ids="35674">antihypertensive</z:chebi> therapy (CT) compared with placebo and CT on the economic cost associated with <z:hpo ids='HP_0003774'>end-stage renal disease</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ESRD</z:e>) </plain></SENT>
<SENT sid="1" pm="."><plain>RESEARCH DESIGN AND METHODS: The Reduction of End Points in Type 2 <z:mp ids='MP_0002055'>Diabetes</z:mp> With the <z:chebi fb="0" ids="2719,48432">Angiotensin II</z:chebi> <z:chebi fb="68" ids="48706">Antagonist</z:chebi> <z:chebi fb="0" ids="6541">Losartan</z:chebi> (RENAAL) study was a multinational double-blind randomized placebo-controlled clinical trial designed to evaluate the renal protective effects of <z:chebi fb="0" ids="6541">losartan</z:chebi> on a background of CT (excluding <z:chebi fb="2" ids="35457">ACE inhibitors</z:chebi> and <z:chebi fb="0" ids="2719,48432">angiotensin II</z:chebi> receptor <z:chebi fb="4" ids="48705">agonists</z:chebi> [AIIAs]) in patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> and <z:hpo ids='HP_0000112'>nephropathy</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>The primary composite end point was doubling of serum <z:chebi fb="0" ids="16737">creatinine</z:chebi>, <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ESRD</z:e>, or <z:hpo ids='HP_0011420'>death</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>Data on the duration of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ESRD</z:e> were used to estimate the economic benefits of slowing the progression of <z:hpo ids='HP_0000112'>nephropathy</z:hpo> </plain></SENT>
<SENT sid="4" pm="."><plain>The cost associated with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ESRD</z:e> was estimated by combining the days each patient experienced <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ESRD</z:e> with the cost of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ESRD</z:e> over time </plain></SENT>
<SENT sid="5" pm="."><plain>The cost of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ESRD</z:e> for individuals with <z:mp ids='MP_0002055'>diabetes</z:mp> was estimated using data from the U.S </plain></SENT>
<SENT sid="6" pm="."><plain>Renal Data System </plain></SENT>
<SENT sid="7" pm="."><plain>Total cost was estimated as the sum of the cost associated with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ESRD</z:e> and the cost of study therapy </plain></SENT>
<SENT sid="8" pm="."><plain>RESULTS-We estimated that <z:chebi fb="0" ids="6541">losartan</z:chebi> and CT compared with placebo and CT reduced the number of days with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ESRD</z:e> by 33.6 per patient over 3.5 years (P = 0.004, 95% CI 10.9-56.3) </plain></SENT>
<SENT sid="9" pm="."><plain>This reduction in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ESRD</z:e> days resulted in a decrease in cost associated with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ESRD</z:e> of 5144 US dollars per patient (P = 0.003, 95% CI 1701 to 8587 US dollars) </plain></SENT>
<SENT sid="10" pm="."><plain>After accounting for the cost of <z:chebi fb="0" ids="6541">losartan</z:chebi>, the reduction in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ESRD</z:e> days resulted in a net savings of 3522 US dollars per patient over 3.5 years (P = 0.041, 143 to 6900 US dollars) </plain></SENT>
<SENT sid="11" pm="."><plain>CONCLUSIONS: Treatment with <z:chebi fb="0" ids="6541">losartan</z:chebi> in patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> and <z:hpo ids='HP_0000112'>nephropathy</z:hpo> not only reduced the incidence of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ESRD</z:e>, but also resulted in substantial cost savings </plain></SENT>
</text></document>